Category: Regions

Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society
September 5, 2019 Off

Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society

By BusinessWire

Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments, along with patient survey results and post hoc efficacy results following the 1-year Phase III HALO long-term study

European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union
September 4, 2019 Off

European Commission Approves Expanded Use of Janssen’s STELARA for the Treatment of Moderately to Severely Active Ulcerative Colitis in the European Union

By BusinessWire

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis (UC), who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.

Vertex buys Semma Therapeutics for $950M
September 3, 2019 Off

Vertex buys Semma Therapeutics for $950M

By Dino Mustafić

Vertex Pharmaceuticals Incorporated will acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.